全文获取类型
收费全文 | 8614篇 |
免费 | 839篇 |
国内免费 | 87篇 |
出版年
2022年 | 36篇 |
2021年 | 167篇 |
2020年 | 108篇 |
2019年 | 136篇 |
2018年 | 151篇 |
2017年 | 138篇 |
2016年 | 248篇 |
2015年 | 448篇 |
2014年 | 428篇 |
2013年 | 527篇 |
2012年 | 684篇 |
2011年 | 627篇 |
2010年 | 385篇 |
2009年 | 345篇 |
2008年 | 462篇 |
2007年 | 416篇 |
2006年 | 428篇 |
2005年 | 375篇 |
2004年 | 328篇 |
2003年 | 306篇 |
2002年 | 254篇 |
2001年 | 235篇 |
2000年 | 226篇 |
1999年 | 179篇 |
1998年 | 75篇 |
1997年 | 54篇 |
1996年 | 68篇 |
1995年 | 57篇 |
1994年 | 46篇 |
1993年 | 59篇 |
1992年 | 124篇 |
1991年 | 95篇 |
1990年 | 100篇 |
1989年 | 108篇 |
1988年 | 77篇 |
1987年 | 83篇 |
1986年 | 88篇 |
1985年 | 90篇 |
1984年 | 62篇 |
1983年 | 62篇 |
1982年 | 50篇 |
1981年 | 49篇 |
1980年 | 46篇 |
1979年 | 76篇 |
1978年 | 60篇 |
1977年 | 45篇 |
1976年 | 48篇 |
1975年 | 36篇 |
1974年 | 43篇 |
1973年 | 41篇 |
排序方式: 共有9540条查询结果,搜索用时 15 毫秒
1.
Daw-Yang Hwang Stefan Kohl Xueping Fan Asaf Vivante Stefanie Chan Gabriel C. Dworschak Julian Schulz Albertien M. van Eerde Alina C. Hilger Heon Yung Gee Tracie Pennimpede Bernhard G. Herrmann Glenn van de Hoek Kirsten Y. Renkema Christoph Schell Tobias B. Huber Heiko M. Reutter Neveen A. Soliman Natasa Stajic Radovan Bogdanovic Elijah O. Kehinde Richard P. Lifton Velibor Tasic Weining Lu Friedhelm Hildebrandt 《Human genetics》2015,134(8):905-916
2.
3.
We consider adaptive robust methods for lung cancer that are also dose-reactive, wherein the treatment is modified after each treatment session to account for the dose delivered in prior treatment sessions. Such methods are of interest because they potentially allow for errors in the delivered dose to be corrected as the treatment progresses, thereby ensuring that the tumor receives a sufficient dose at the end of the treatment. We show through a computational study with real lung cancer patient data that while dose reaction is beneficial with respect to the final dose distribution, it may lead to exaggerated daily underdose and overdose relative to non-reactive methods that grows as the treatment progresses. However, by combining dose reaction with a mechanism for updating an estimate of the uncertainty, the magnitude of this growth can be mitigated substantially. The key finding of this paper is that reacting to dose errors – an adaptation strategy that is both simple and intuitively appealing – may backfire and lead to treatments that are clinically unacceptable. 相似文献
4.
5.
6.
7.
Maurice Chan 《Biochemical and biophysical research communications》2004,326(1):188-196
The important role of pyruvate kinase during malarial infection has prompted the cloning of a cDNA encoding Plasmodium falciparum pyruvate kinase (pfPyrK), using mRNA from intraerythrocytic-stage malaria parasites. The full-length cDNA encodes a protein with a computed molecular weight of 55.6 kDa and an isoelectric point of 7.5. The purified recombinant pfPyrK is enzymatically active and exists as a homotetramer in its active form. The enzyme exhibits hyperbolic kinetics with respect to phosphoenolpyruvate and ADP, with Km of 0.19 and 0.12 mM, respectively. pfPyrK is not affected by fructose-1,6-bisphosphate, a general activating factor of pyruvate kinase for most species. Glucose-6-phosphate, an activator of the Toxoplasma gondii enzyme, does not affect pfPyrK activity. Similar to rabbit pyruvate kinase, pfPyrK is susceptible to inactivation by 1 mM pyridoxal-5′-phosphate, but to a lesser extent. A screen for inhibitors to pfPyrK revealed that it is markedly inhibited by ATP and citrate. Detailed kinetic analysis revealed a transition from hyperbolic to sigmoidal kinetics for PEP in the presence of citrate, as well as competitive inhibitory behavior for ATP with respect to PEP. Citrate exhibits non-competitive inhibition with respect to ADP with a Ki of 0.8 mM. In conclusion, P. falciparum expresses an active pyruvate kinase during the intraerythrocytic-stage of its developmental cycle that may play important metabolic roles during infection. 相似文献
8.
9.
10.